Effects of L-dopa and bromocriptine on haloperidol-induced motor deficits in mice - PubMed (original) (raw)
Effects of L-dopa and bromocriptine on haloperidol-induced motor deficits in mice
T Kobayashi et al. Life Sci. 1997.
Abstract
L-3,4-Dihydroxyphenylalanine (L-DOPA), the precursor of dopamine, and bromocriptine, a dopamine D2 receptor agonist, were investigated in haloperidol-induced motor impairments in mice using both catalepsy and pole tests. In catalepsy test, subcutaneous treatment with haloperidol (0.125, 0.25 and 0.5 mg/kg) caused a cataleptic effect in mice in a dose-dependent manner. This cataleptic effect was evident upto 7 hr after haloperidol treatment. In pole test, haloperidol (0.125, 0.25 and 0.5 mg/kg) produced the prolongation of Tturn and TLA as a marker of bradykinesia in mice and the prolongation lasted at least 7 hr after haloperidol treatment. Intraperitoneal co-pretreatment with L-DOPA (400 mg/kg) + carbidopa (10 mg/kg) in mice decreased the catalepsy induced by haloperidol at a dose of 0.125 mg/kg, while co-pretreatment with L-DOPA (200 and 400 mg/kg) + carbidopa (10 mg/kg) dose-dependently decreased the haloperidol (0.125 mg/kg)-induced bradykinesia. The effect of LDOPA + carbidopa in pole test was more pronounced than that in catalepsy test. Intraperitoneal pretreatment with bromocriptine (2 and 4 mg/kg) in mice reduced the catalepsy and bradykinesia produced by haloperidol at a dose of 0.125 mg/kg. The effect of bromocriptine in pole test was relatively similar to that in catalepsy test. Also, co-pretreatment with LDOPA (400 mg/kg) + carbidopa (10 mg/kg) and pretreatment with bromocriptine (2 and 4 mg/kg) significantly decreased the catalepsy induced by haloperidol at a higher dose of 0.5 mg/kg. These results indicate that co-administration with L-DOPA + carbidopa and single treatment with bromocriptine can decrease haloperidol-induced catalepsy and bradykinesia in mice. Furthermore, our study suggests that pole test as well as catalepsy test is of value in the screening of drugs against neuroleptic-induced motor deficits.
Similar articles
- Modification of cataleptic responses to dopamine receptor antagonists after withdrawal from chronic cocaine or cocaine plus dopamine antagonist administration.
Ushijima I, Mizuki Y, Suetsugi M, Akimoto T, Yamada M. Ushijima I, et al. Prog Neuropsychopharmacol Biol Psychiatry. 1998 May;22(4):709-21. doi: 10.1016/s0278-5846(98)00034-7. Prog Neuropsychopharmacol Biol Psychiatry. 1998. PMID: 9682282 - Alteration of cataleptic responses induced by dopamine receptor antagonists after chronic cocaine administration in mice.
Ushijima I, Mizuki Y, Yamada M. Ushijima I, et al. Eur J Pharmacol. 1995 Oct 4;285(1):55-9. doi: 10.1016/0014-2999(95)00382-u. Eur J Pharmacol. 1995. PMID: 8846811 - Endogenous neurotensin attenuates dopamine-dependent locomotion and stereotypy.
Chartoff EH, Szczypka MS, Palmiter RD, Dorsa DM. Chartoff EH, et al. Brain Res. 2004 Oct 1;1022(1-2):71-80. doi: 10.1016/j.brainres.2004.06.061. Brain Res. 2004. PMID: 15353215 - [Regulation of dopaminergic neuronal activity by heart-type fatty acid binding protein in the brain].
Yamamoto Y, Shioda N, Owada Y, Fukunaga K. Yamamoto Y, et al. Yakugaku Zasshi. 2011 Apr;131(4):497-501. doi: 10.1248/yakushi.131.497. Yakugaku Zasshi. 2011. PMID: 21467787 Review. Japanese. - Haloperidol-induced catalepsy as an animal model for parkinsonism: A systematic review of experimental studies.
Waku I, Magalhães MS, Alves CO, de Oliveira AR. Waku I, et al. Eur J Neurosci. 2021 Jun;53(11):3743-3767. doi: 10.1111/ejn.15222. Epub 2021 Apr 25. Eur J Neurosci. 2021. PMID: 33818841 Review.
Cited by
- Histamine- and haloperidol-induced catalepsy in aged mice: differential responsiveness to L-DOPA.
Ionov ID, Severtsev NN. Ionov ID, et al. Psychopharmacology (Berl). 2012 Sep;223(2):191-7. doi: 10.1007/s00213-012-2706-0. Epub 2012 Apr 13. Psychopharmacology (Berl). 2012. PMID: 22526536 - Animal models of Parkinson's disease: a source of novel treatments and clues to the cause of the disease.
Duty S, Jenner P. Duty S, et al. Br J Pharmacol. 2011 Oct;164(4):1357-91. doi: 10.1111/j.1476-5381.2011.01426.x. Br J Pharmacol. 2011. PMID: 21486284 Free PMC article. Review. - The effect of docosahexaenoic Acid on visual evoked potentials in a mouse model of Parkinson's disease: the role of cyclooxygenase-2 and nuclear factor kappa-B.
Ozsoy O, Tanriover G, Derin N, Uysal N, Demir N, Gemici B, Kencebay C, Yargicoglu P, Agar A, Aslan M. Ozsoy O, et al. Neurotox Res. 2011 Oct;20(3):250-62. doi: 10.1007/s12640-011-9238-y. Epub 2011 Jan 14. Neurotox Res. 2011. PMID: 21234736